ReviewFrontiers in pharmacology2025

Indoleamine 2,3-dioxygenase 1 in cancer immunotherapy: from small-molecule inhibition to PROTAC-mediated degradation.

Xiuyun Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.